Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 7Glioblastoma 4Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Rare Tumour 1Neuroectodermal Tumors 1Nervous System Diseases 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoadjuvant Therapy 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Locally Advanced Prostate Cancer 1Limited Stage Small Cell Lung Cancer 1Hereditary leiomyomatosis and renal cell cancer 1HER2-negative Breast Cancer 1Gliosarcoma 1Glioma 1For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment 1Esophageal Neoplasms 1Central Nervous System Neoplasms 1Carcinosarcoma 1

Interventions

pembrolizumab 1pamiparib 1famitinib 1enzalutamide 1apalutamide 1abiraterone 1Prednisone 1Prednisolone 1Poly(ADP-ribose) Polymerase Inhibitors 1Neoadjuvant Therapy 1Folfox protocol 1Fluorouracil 1Drug Therapy 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoadjuvant Therapy × pamiparib × Clear all
NCT05376722 2023-01-05

A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Unknown
30 enrolled

Neoadjuvant Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡